CS
KERX

Candriam SCA’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Candriam SCA’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-390,000
Closed -$4.97M – 679
2015
Q1 		$4.97M Hold
390,000
– – 0.1% 256
2014
Q4 		$5.52M Buy
+390,000
New +$6.04M 0.12% 216

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Candriam SCA's KERX Position: Q2 2015 in Review

Candriam SCA sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2015, closing a stake of 390,000 shares — an estimated $4.97M sold.

Candriam SCA first reported a position in KERX in Q4 2014 and held it in 2 quarters. The position peaked at $5.52M in Q4 2014. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

  • Candriam SCA reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • Candriam SCA sold 390,000 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $4.97M.
  • Candriam SCA first reported a position in Keryx Biopharmaceuticals Inc in Q4 2014 and held it in 2 quarters.
  • Candriam SCA's Keryx Biopharmaceuticals Inc position peaked at $5.52M in Q4 2014.
  • 153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on Candriam SCA's 13F filing for Q2 2015, filed 29 Jul 2015.